Compare INSG & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INSG | NRXS |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 76.9M |
| IPO Year | 2000 | 2023 |
| Metric | INSG | NRXS |
|---|---|---|
| Price | $3.01 | $4.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $9.17 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 230.9K | 146.5K |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $313,832,000.00 | $3,569,282.00 |
| Revenue This Year | N/A | $118.53 |
| Revenue Next Year | $10.21 | $101.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $3.30 | $2.50 |
| 52 Week High | $21.90 | $9.33 |
| Indicator | INSG | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 32.52 | 26.87 |
| Support Level | N/A | N/A |
| Resistance Level | $4.68 | $7.79 |
| Average True Range (ATR) | 0.40 | 0.55 |
| MACD | -0.14 | -0.22 |
| Stochastic Oscillator | 0.49 | 2.96 |
Inseego Corp is involved in the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things, and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by application software and cloud services designed to enable customers to analyze data insights and configure and manage their hardware easily. It generates maximum revenue from the United States and Canada. The company also has a presence in Europe (including the United Kingdom).
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).